iNtRON Biotechnology, Inc. (KOSDAQ:048530)
3,775.00
-20.00 (-0.53%)
At close: Dec 5, 2025
iNtRON Biotechnology Revenue
iNtRON Biotechnology had revenue of 1.62B KRW in the quarter ending September 30, 2025, with 34.35% growth. This brings the company's revenue in the last twelve months to 5.56B, down -35.49% year-over-year. In the year 2024, iNtRON Biotechnology had annual revenue of 6.42B, down -33.05%.
Revenue (ttm)
5.56B
Revenue Growth
-35.49%
P/S Ratio
21.47
Revenue / Employee
76.13M
Employees
71
Market Cap
119.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.42B | -3.17B | -33.05% |
| Dec 31, 2023 | 9.59B | -4.42B | -31.57% |
| Dec 31, 2022 | 14.01B | -15.30B | -52.21% |
| Dec 31, 2021 | 29.31B | -16.13B | -35.49% |
| Dec 31, 2020 | 45.43B | 37.09B | 444.28% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |